Joshua Young
Keine laufenden Positionen mehr
Profil
Joshua Young worked as a Director of Investor Relations at EMD Millipore Corp.
from 2005 to 2010, as a Director of IR & Corporate Development at AspenTech Corp.
from 1998 to 2005, and as a Manager of IR & Corporate Communications at Oscient Pharmaceuticals Corp.
in 1997.
He also worked as a VP of Investor Relations & Corporate Development at Bruker Corp.
from 2015 to 2016 and as a Vice President of Investor Relations at Sensata Technologies Holding Plc.
Mr. Young received his undergraduate degree from Syracuse University in 1997 and his MBA from the Wallace E Carroll School of Management in 2003.
Ehemalige bekannte Positionen von Joshua Young
| Unternehmen | Position | Ende |
|---|---|---|
| BRUKER CORPORATION | Investor Relations Kontakt | 01.06.2016 |
EMD Millipore Corp.
 EMD Millipore Corp. Miscellaneous Commercial ServicesCommercial Services EMD Millipore Corp. engages in the provision of laboratory materials, technologies, and services to the life science industry. The company was founded by Jack Bush in 1954 and is headquartered in Burlington, MA. | Investor Relations Kontakt | 01.07.2010 |
| ASPEN TECHNOLOGY | Investor Relations Kontakt | 01.09.2005 |
Oscient Pharmaceuticals Corp.
 Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA. | Investor Relations Kontakt | 01.01.1998 |
| SENSATA TECHNOLOGIES HOLDING PLC | Public Communications Contact | - |
Ausbildung von Joshua Young
| Wallace E Carroll School of Management | Masters Business Admin |
| Syracuse University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| SENSATA TECHNOLOGIES HOLDING PLC | Electronic Technology |
| BRUKER CORPORATION | Health Technology |
| Private Unternehmen | 3 |
|---|---|
EMD Millipore Corp.
EMD Millipore Corp. Miscellaneous Commercial ServicesCommercial Services EMD Millipore Corp. engages in the provision of laboratory materials, technologies, and services to the life science industry. The company was founded by Jack Bush in 1954 and is headquartered in Burlington, MA. | Commercial Services |
AspenTech Corp.
 AspenTech Corp. Packaged SoftwareTechnology Services AspenTech Corp. engages in the provision of asset optimization solutions. It develops its applications to design, and optimize processes across the engineering, manufacturing, supply chain, and asset performance management areas. The firm operates through the Subscription and Software, and Services and Other segments. The Subscription and Software segment offers licensing of process optimization, asset performance management software solutions and associated support services. The Services and Other segment includes professional services, and training. The company was founded in 1981 and is headquartered in Bedford, MA. | Technology Services |
Oscient Pharmaceuticals Corp.
Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA. | Commercial Services |
